TEVA.TA Teva Pharmaceutical Industries Limited
Company Analysis
Latest News
🔴 Teva Pharmaceuticals is trading 4.12% down
Teva Pharmaceuticals is trading 4.12% down at ILA 12,320.00 on October 21, 2026, with no clear cause established by the available evidence. - Available...
🟢 Teva Pharmaceuticals is trading 5% up today as FDA approval of WELTRUZA fuels buying
Teva Pharmaceuticals is trading 5.25% up at ILA 12,630.00, with buying continuing after the FDA’s October 9 approval of WELTRUZA, its once-monthly injectable...
🟢 Teva Pharmaceuticals up 5% on continued positive sentiment from WELTRUZA™ FDA approval
Teva Pharmaceuticals is trading at ILA 12610.00, up 5.08%. The rise follows continued positive market reaction to the FDA approval of WELTRUZA™ (olanzapine)...
Teva Loses RCN Partnership Over Values Concerns
The UK's Royal College of Nursing (RCN), which represents more than 500,000 nurses, has ended its commercial partnership with Teva UK. The RCN said due...
Teva Wins FDA Approval for DEGEVMA, an Xgeva Biosimilar
Teva Pharmaceutical Industries received U.S. Food and Drug Administration (FDA) approval for DEGEVMA™ (denosumab-adet), a biosimilar to Amgen’s Xgeva®. The...
Teva Pivots to Growth, Saving $400 Million After Early Credit Upgrade
Teva Pharmaceutical Industries CEO Richard Francis detailed a refined growth strategy at the Bank of America Global Healthcare Conference. All three major...
Teva Wins ₹783 Crore Tax Refund, Ending 9-Year Ranbaxy Dispute
The Delhi High Court quashed tax proceedings against Teva Pharmaceutical Industries and its U.S. affiliate. This ruling concludes a legal battle spanning...
Teva completes direct NYSE listing, expanding investor access
Teva Pharmaceutical Industries began trading ordinary shares directly on the New York Stock Exchange (NYSE) on September 14, 2026. This move completes the...
Teva Prices $4.9 Billion Debt Offering to Cut Interest Costs
Teva Pharmaceutical Industries Ltd. priced a senior notes offering totaling approximately $4.9 billion. The issuance includes multiple tranches denominated in...
Teva gains Leerink Outperform rating as major fund builds $33.8M stake
Leerink Partners initiated coverage of Teva Pharmaceutical Industries with an Outperform rating. The investment bank set a price target of $45 for the...
🟢 Teva Pharmaceuticals is trading 4.26% up today after positive Phase 2a celiac-disease results
Teva Pharmaceuticals is trading 4.26% up now at ILA 11490.00 after positive topline Phase 2a results for TEV ’408, an investigational anti-IL-15 antibody for...
Teva bids $125 million for BioXcel drug, expanding its psychiatry portfolio
Teva Pharmaceutical Industries Ltd. submitted a stalking horse bid to acquire a neuroscience asset from BioXcel Therapeutics through a bankruptcy sale. The...
Teva faces Turkish antitrust probe, accused of blocking generic drug rivals
Turkish competition authorities launched an investigation into Teva Pharmaceutical Industries for alleged anti-competitive practices. The probe focuses on...
Teva Secures FDA Priority Review, Seeking First Tourette Treatment in a Decade
The FDA accepted Teva Pharmaceutical Industries’ New Drug Application for ecopipam. The agency granted the investigational, first-in-class pediatric Tourette...
🟢 Teva Pharmaceuticals is trading 4.04% up today after Moody’s upgrade to investment grade
Teva Pharmaceuticals is trading now 4.04% up at ILA 11080.00 after Moody’s Ratings upgraded its corporate credit rating to Baa3 from Ba1 with a stable...
🔴 Teva Pharmaceuticals is trading 4.1% down today on profit-taking after earnings-driven rally
Teva Pharmaceuticals is trading 4.1% down at ILA 10,430 as investors take profits following last week’s sharp earnings-driven rally. • Shares recently surged...
🔴 Teva Pharmaceuticals is trading 4.5% down today on profit-taking after recent gains
Teva Pharmaceuticals is trading 4.5% down at ILA 10,380 as investors lock in profits following a significant rally last week. • The stock recently surged...
Teva Beats Estimates and Raises Its Drug Outlook — But Can Branded Growth Outrun the Generics Decline?
Shares surged 10.5% to ₪10,590 on the Tel Aviv Stock Exchange as Teva Pharmaceutical delivered Q2 2026 results that cleared a low bar set by analysts expecting...
🟢 Teva Pharmaceuticals is trading 10.5% up today after beating Q2 2026 earnings estimates
Teva Pharmaceuticals is trading 10.5% up today at $10,590 after releasing better-than-expected Q2 2026 results and hosting its earnings conference call. • The...
🟢 Teva Pharmaceuticals is trading 4.1% up today after Q2 2026 earnings
Teva Pharmaceuticals is trading 4.1% up at $9,980 after releasing second-quarter 2026 financial results and holding a conference call on July 29, 2026. • The...